Related Experiment Video
Updated: Jul 7, 2026
08:16
Partial Sciatic Nerve Ligation: A Mouse Model of Chronic Neuropathic Pain to Study the Antinociceptive Effect of Novel Therapies
Published on: October 6, 2022
Peripheral cannabinoids attenuate carcinoma-induced nociception in mice
Andre V Guerrero1, Phuong Quang, Nusi Dekker
1UCSF School of Dentistry, University of California, Sa Francisco, CA 94143-0440, United States.
Neuroscience Letters
|February 5, 2008
Summary
Cannabinoids, including non-selective Win55,212-2 and selective AM1241, effectively reduced carcinoma-induced pain in mice. This suggests potential therapeutic benefits for cannabinoid receptor 1 (CBr1) agonists in managing cancer pain.
Area of Science:
- Pharmacology
- Pain Research
- Oncology
Background:
- Carcinoma-induced pain is a significant challenge in cancer care.
- Cannabinoid receptors (CBr) are implicated in pain modulation.
- Understanding CBr1 involvement in cancer pain is crucial for developing novel analgesics.
Purpose of the Study:
- To investigate the antinociceptive effects of cannabinoid receptor agonists in a mouse model of carcinoma-induced pain.
- To explore the role of cannabinoid receptor 1 (CBr1) in this pain model.
Main Methods:
- A mouse model of oral squamous cell carcinoma (SCC) was established in the hind paw.
- Mechanical withdrawal thresholds were measured to assess pain.
- Local administration of Win55,212-2 (non-selective CBr agonist) and AM1241 (CBr2 selective agonist) was performed.
- CBr1 protein expression in dorsal root ganglia (DRG) was analyzed.
Main Results:
- SCC inoculation led to significant pain, indicated by reduced withdrawal thresholds from day 4 to 18.
- Both Win55,212-2 and AM1241 significantly increased withdrawal thresholds, demonstrating antinociceptive effects.
- Ipsilateral CBr1 protein expression was significantly upregulated in L5 DRG compared to L4 DRG and normal tissue.
Conclusions:
- Cannabinoid receptor agonists exhibit antinociceptive properties in carcinoma-induced pain.
- CBr1 upregulation in DRG suggests its involvement in mediating cancer pain.
- These findings support the potential of cannabinoids as therapeutic agents for cancer pain management.
Related Concept Videos
01:21Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
01:44Nociception
Nociception—the ability to feel pain—is essential for an organism’s survival and overall well-being. Noxious stimuli such as piercing pain from a sharp object, heat from an open flame, or contact with corrosive chemicals are first detected by sensory receptors, called nociceptors, located on nerve endings. Nociceptors express ion channels that convert noxious stimuli into electrical signals. When these signals reach the brain via sensory neurons, they are perceived as pain. Thus, pain helps the...
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...
01:25Analgesia and Pain Management
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...